Mobile

Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice

Mise à jour : Il y a 5 ans
Référence : NCT01492166

Femme et Homme

  • | Pays :
  • Indonesia
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

This study is conducted in Asia. The aim of this study is to assess the efficacy, safety and convenience of the use of Mixtard® 30 NovoLet® used alone or combined with oral hypoglycaemic agent (OHA) in the management of type 2 diabetes mellitus in an out-patient setting.

Critère d'inclusion

  • diabetes ,Diabetes Mellitus, Type 2

Liens